Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 1 of 17

Bibliography Papers Developed and/or Edited by Robert J. Marlowe/Spencer-Fontayne Corporation

Abernathy, E. Biotherapy: an introductory overview. Onc Nurs Forum 1987, 14(6Suppl):13-15.

Aerts JFMG, Boot RG, Renkema GH, van Weely S, Jones S, Hollak CEM, van Oers MHJ. Molecular and biochemical abnormalities of Gaucher disease: chirotriosidase, a newly identified biochemical marker. Seminars in Hematology 1995; 32(3 Suppl 1):10-13.

Alzahrani A, AlShaikh O, Tuli M, Al-Sugair A, Al-Awami R, Al-Rasheed M. Diagnostic value of recombinant human TSH-stimulated iodine-123 whole-body scintigraphy in patients with differentiated thyroid cancer. Clin Nucl Med 2012; 37:229-234.

Andermann P, Schlögl S, Mäder U, Luster M, Lassmann M, Reiners C. Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound. Nuklearmedizin 2007; 46:1-7.

Annane D, Maxime V, Faller JP, Mezher C, Clec’h C, Martel P, Gonzales H, Feissel M, Cohen Y, Capellier G, Gharbi M, Nardi O.Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial BMJ Open 2013;3:e002186. doi:10.1136/bmjopen-2012-002186.

Banach R, Bartès B, Farnell K, Rimmele H, Shey J, Singer S, Verburg FA, Luster M, for the Thyroid Cancer Alliance. Psychosocial/informational support needs, treatment side effects, and international differences in care: results of the Thyroid Cancer Alliance international patient/survivor survey. Hormones 2013; 12:428-438.

Bauerschlag DO, Maass N, Leonhardt P, Verburg FA, Pecks U, Zeppernick F, Morgenroth A, Mottaghy FM, Tolba R, Meinhold-Heerlein I, Bräutigam K. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. J Transl Med 2015; 13:146.

Beck DE. The role of Seprafilm™ bioresorbable membrane in adhesion prevention. Eur J Surgery 1997; 163 (Suppl 577):49-55.

Belmatoug N, Billette de Villemeur T for the Comité d’Evaluation du Traitement par la Cérédase. Skeletal response to enzyme replacement therapy for type 1 Gaucher disease: a preliminary report of the French experience. Seminars in Hematology 1995; 32(3 Suppl 1):33-38.

Berg G, Lindstedt G, Suurküla M., Jansson S, Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002; 25:44-52.

Boyle DM. New identities: the changing profile of patients with cancer, their families and their professional caregivers. Onc Nurs Forum 1994; 21(1):55-61.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 2 of 17

Boyle DM, Engelking C, Harvey C. Taking command of the future: getting ready NOW for the 21st century. Onc Nurs Forum 1994; 21(1):77-79.

Brophy LR & Sharp EJ. Physical symptoms of combination biotherapy: a quality-of-life issue.Onc Nurs Forum 1991; 18(1Suppl):25-30.

Burns JW, Colt MJ, Burgess LS, Skinner KC. Preclinical evaluation of Seprafilm™ bioresorbable membrane. Eur J Surgery 1997; 163 (Suppl 577):40-48.

Calzone KA. Genetic predisposition testing: clinical implications for oncology nurses. Onc Nurs Forum 1997; 24(4):712-718.

Carsin H, Ainaud P, le Bever H, Rives J, Lakhel A, Stephanazzi J, Lambert F, Perrot J. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. Burns 2000; 26(4):379-387.

Caudell KA. Psychoneuroimmunology and innovative behavioral interventions in patients with leukemia. Onc Nurs Forum 1996; 23(3):493-506.

Champlin R. The role of bone marrow transplantation for nuclear accidents: implications of the Chernobyl disaster. Semin Hematol 1987; 24(Suppl 2):1-4.

Chegini N. The role of growth factors in peritoneal healing: transforming growth factor (TGF-β) Eur J Surgery 1997; 163 (Suppl 577):17-23.

Charrow J, Esplin JA, Gribble J, Kaplan P, Kolodny, EH, Pastores GM, Scott R, Wappner RS, Weinreb NJ, Wisch JS. Gaucher disease: recommendations on diagnosis evaluation and monitoring. Arch Intern Med, 1998; 158:1754-1760.

Christou A, Papastavrou E, Merkouris A, Frangos S, Tamana P, Charalambous A. Clinical studies of nonpharmacological methods to minimize salivary gland damage after radioiodine therapy of differentiated thyroid carcinoma: systematic review. Ev-Based Complement Altern Med 2016; Volume 2016, Article ID 6795076.

Clerc J, Bienvenu-Perrard M, Pichard de Malleray C, Dagousset F, Delbot T, Dreyfuss M, Groussin L, Marlowe RJ, Leger FA, Chevalier A. Outpatient thyroid remnant ablation using repeated low 131-iodine activities (740 MBq/20 mCi x 2) in patients with low-risk differentiated thyroid cancer. J Clin Endocrinol Metab 2012; 97:871-880.

Cohen O, Dabhi S, Tzwas T, Karasik A. Compliance with follow-up and informativeness of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocrinol 2004; 150:285-290.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 3 of 17

Cohen O, Ilany J, Hoffman C, Olchovsky D, Dabhi S, Karasik A, Goshen E, Rotenberg G, Zwas ST. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol 2006; 154:243-252.

Cohen O, Körner A, Chlup R, Zoupas CS, Ragozin AK, Wudi K, Bartaskova D, Pappas A, Niederland T, Taybani Z, Barák L, Vazeou A for the Central and Eastern Europe, Greece and Israel Continuous Glucose Sensing Collaborative Study Group. Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: prospective results from a community and academic practice patient registry. J Diabet Sci Technol, 2009; 3(4):804-811.

Darr AM, Opfermann T, Niksch T, Driesch D, Marlowe RJ, Freesmeyer M. Low-activity I-124-positron emission tomography/low-dose computed tomography versus Tc-99m pertechnetate-planar scintigraphy or Tc-99m pertechnetate-single photon emission computed tomography of the thyroid: a pilot comparison. Clin Nucl Med 2013; 38:770-777.

de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJM, de Klerk JMH. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer J Nucl Med 2004; 45:1549–1554.

Desnick RJ. Fabry disease and other lysosomal storage disorders: enzyme replacement and beyond. Journal of Inherited Metabolic Disease 2001; 24: 251-265.

Desnick RJ. Fabry disease: clinical features and recent advances in enzyme replacement therapy. Actualités Néphrologiques de l’Hôpital Necker, 2001.

Diamond MP and the Sepracoat Adhesion Study Group. Reduction of de novo postsurgical adhesions by intraoperative precoating with Sepracoat* (Hal-C) solution: a prospective, randomized, blinded, placebo-controlled multicenter study. Fertility and Sterility 1998; 69(6):1067-1074.

Dießl S, Verburg FA, Biko J, Schryen B, Reiners C, Buck AK, Hänscheid H. Improved follow-up of patients with differentiated thyroid carcinoma: the quantitative detection limit of I-131 uptake in diagnostic scans. Nuklearmedizin 2013; 52(2).

Dietlein M,Verburg FA, Luster M, Reiners C, Pitoia F, Schicha H. One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer [editorial]. Eur J Nucl Med Mol Imaging 2011; 38:793-798.

DiZerega GS. Biochemical events in peritoneal tissue repair. Eur J Surgery 1997; 163 (Suppl 577):10-17.

Doyle P, Düren C, Nerlich K, Verburg FA, Grelle I, Jahn H, Fassnacht M, Mäder U, Reiners C, Luster M. Potency and tolerance of calcitonin stimulation with high dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab 2009; 94: 2970-2974.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 4 of 17

Drescher R, Freesmeyer M. PET angiography: application of early dynamic PET/CT to the evaluation of arteries. AJR 2013; 201:908–911.

Drozd V, Leonova T, Mitjukova T, Lushchik M, Koritko S, Magner JA, Biko J, Reiners C. Recombinant human thyrotropin to help confirm lack of evidence of radiation-induced differentiated thyroid cancer in young women seeking pregnancy Nucl Med Rev Cent East Europe 2012; 15:108-112.

Duursma SJ, Aerts MFG, Belmatoug N, Cox TM, Einhorn TA, Esplin JA, Hollak CEM, Pastores GM, Rademakers RP, Zaizov R. Management of Gaucher disease: current status and future directions: a roundtable discussion. Seminars in Hematology 1995; 32(3 Suppl 1):45-52.

Ellis H. The clinical significance of adhesions: focus on intestinal obstruction. Eur J Surgery 1997; 163 (Suppl 577):5-9.

Eng CM, Cochat P, Wilcox WR, Lee P, Germain DP, Waldek S, Caplan L, Heymans H, Desnick RJ. Safety and efficacy of recombinant human α-Galactosidase A-replacement therapy in Fabry disease. New Engl J Med 2001; 345:9-16.

Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O’Callaghan M, Desnick RJ. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance and safety studies. Am J Hum Genet 2001; 68: 711-722.

Engelking C. Genetics in cancer care: confronting a Pandora’s box of dilemmas. Onc Nurs Forum 1995; 22(2 Suppl):27-34.

Engelking C. The human genome exposed: a glimpse of promise, predicament and impact on practice. Onc Nurs Forum 1995; 22(2 Suppl):3-9.

Engelking C. New approaches: innovations in cancer prevention, diagnosis, treatment, and support. Onc Nurs Forum 1994; 21(1): 62-71. Esplin JA. Clinical effects of enzyme replacement therapy for Gaucher disease: a review of various dosing regimens. Seminars in Hematology 1995; 32(3 Suppl 1):28-32. Figlin RA. Biotherapy with interferon in solid tumors. Onc Nurs Forum 1987; 14(6Suppl):23-26.

Esquivias-Motta E, Martín-Malo A, Buendía P, Álvarez-Lara MA, Soriano S, Crespo R, Carracedo J, Ramírez R, Aljama P. Hemodiafiltration with endogenous reinfusion improved microinflammation and endothelial damage compared with online-hemodiafiltration: a hypothesis generating study. Artif Organs. 2016 May 16. doi: 10.1111/aor.12704. [Epub ahead of print]

Foon, KA. Biotherapy of cancer with interleukin-2, colony-stimulating factors, and monoclonal antibodies. Onc Nurs Forum 1988; 15(6Suppl):13-22.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 5 of 17

Frangos S, Iakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, Savva A, Mpalaris V, Giannoula EI. Difficulties in deciding whether to ablate patients with putatively “low–intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. Eur J Nucl Med Molec Imag 2015;42:2045-2055.

Frangos S, Iakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, Savva A, Mpalaris V, Giannoula EI. Acknowledging Gray Areas: 2015 vs. 2009 American Thyroid Association Differentiated Thyroid Cancer Guidelines on Ablating Putatively Low-Intermediate-Risk Patients. Eur J Nucl Med Molec Imag 2016; in press.

Freesmeyer M. Regarding dynamic bone imaging with 99mTc-Labeled diphosphonates and 18F-NaF: mechanisms and applications [letter to editor]. J Nucl Med 2013; 54:2190.

Freesmeyer M, Zanow J, Ludewig S, Drescher R. Multimodal imaging of aortoiliac occlusive disease with three-dimensional postprocessing of PET angiography and CT. Clin Imaging 2014; 38: 877–879.

Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, Bockisch A, Görges R. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Molec Imag 2008; 35:950-957.

Freudenberg LS, Beyer T. Subjective Perception of Radiation Risk. J Nucl Med 2011; 52:29S–35S.

Freudenberg, LS, Goertz E, Hagen C, Harms E, Koska WW, Marlowe RJ, Shadou S, Stock C.. Lymphatic mapping using SPECT/CT in vulvar carcinoma. Clin Nucl Med 2010, 35:950-952.

Freudenberg LS, Jentzen W, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, Eising EG, Knust EJ, Bockisch A, et al. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 2010, 118(7):393-399.

Freudenberg LS., Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A. 124I –positron emission tomography dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 2007; 46:121-128.

Freudenberg LF, Jentzen W, Marlowe RJ, Koska WW, Luster M, Bockisch A. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 2007; 115:690-693.

Freudenberg LF, Jentzen W, Müller SP, Bockisch A. Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I-PET. Eur J Nucl Med Molec Imag 2008; 35:502-508.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 6 of 17

Freudenberg LS, Jentzen W; Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I-PET/CT dosimetric comparisons. Eur J Nucl Med Molec Imag 2010; 37:2267-2276.

Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan (CPT-11) dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003, 21:807-814.

Gallucci B. The immune system and cancer. Onc Nurs Forum 1987; 14(6Suppl):3-12.

Gan TJ. Risk factors for postoperative nausea and vomiting [review article]. Anesth Analg 2006;1884-1898.

Gauna A, Messuti H, Papadopulos G, Benchuga G, Viale F, Marlowe RJ, Silva Croome MC. Acute and chronic hypothyroidism are associated with similar left ventricular diastolic dysfunction relative to the euthyroid state: results of doppler echocardiographic comparisons. J Endocrinol Investig, 2011; 34:e281-e286.

Gleeson S. Reimbursement of biotherapy: present status, future directions - perspectives of the third-party payor. Semin Onc Nurs 1992; 8(4 Suppl):13-16.

Grolimund E, Kutz A, Marlowe RJ, Vögeli A, Alan M, Christ-Crain M, Thomann R, Falconnier F, Hoess C, Henzen C, Zimmerli W, Mueller B, Schuetz. P. for the ProHOSP Study Group. Long-term prognosis in COPD exacerbation: Role of biomarkers, clinical variables and exacerbation type. COPD: Journal of Chronic Obstructive Pulmonary Disease 2014; 17 September DOI 10.3109/15412555.2014.949002.

Groopman JE. AIDS-related Kaposi’s sarcoma: therapeutic modalities. Semin Hematol 1987; 24(Suppl 2):5-8.

Groopman JE, Klein HG, Levine PH, Redfield RR, Sande MA. AIDS: questions and controversies - a panel discussion. Semin Hematol 1987; 24(Suppl 2):9-19.

Guivarc’h PH, Vachon MG, Fordyce D. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. Clin Ther 2004; 26:1456-1469.

Habermann TM. Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia. Onc Nurs Forum 1989; 16(6Suppl):8-11.

Haeuber D. Recent advances in the management of biotherapy-related side effects: flu-like syndrome. Onc Nurs Forum 1989; 16(6Suppl): 35-41.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 7 of 17

Handkiewicz-Junak D, Czarniecka A, Jarzab B Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions [Review]. Molecular and cellular Endocrinology 2010; 322:8-28.

Handkiewicz-Junak D, Roskosz J,. Hasse-Lazar K, Szpak-Ulczok S, Puch Z, Kukulska A, Olczyk T, Piela A, Paliczka-Cieslik E, Jarzab B. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Research 2009; 2(1):1-11.

Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulska A, Prokurat A, Wygoda Z, Jarzab B. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 2007; 48:879-888.

Harvey C. New systems: the restructuring of cancer care delivery and economics. Onc Nurs Forum 1994; 21(1): 72-77. Hogan CM. Coping with biotherapy: physiological and psychosocial concerns. Onc Nurs Forum 1991; 18(1Suppl):19-23.

Holmdahl L. The role of fibrinolysis in adhesion formation. Eur J Surgery 1997; 163 (Suppl 577):24-31.

Holmdahl L, Risberg B, Beck DE, Burns JW, Chegini N, diZerega G, Ellis H. Adhesions: pathogenesis and prevention — panel discussion and summary. Eur J Surgery 1997; 163 (Suppl 577):56-62.

Ida H, Rennert OM, Kato S, Ueda T, Oishi K, Maekawa K, Eto Y. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inher Metabol Dis 1999; 22:63-73.

Ida H, Rennert OM, Kobayashi M, Eto Y. Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease. Eur J Pediatr 2001; 160:21-25.

Ida H, Rennert OM, Ito T, Maekawa K, Eto Y. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood, Cells, Molecules and Diseases 1998; 24(5): 73-81.

Incerti C. Gaucher disease: an overview. Seminars in Hematology 1995; 32(3 Suppl 1):3-9.

Incerti C. Recombinant human thyroid-stimulating hormone (rhTSH) clinical development. J Endocrinol Investigation 1999; 22(11 Suppl):8-16.

Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of -galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001; 28:14-25.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 8 of 17

Irwin MM. Patients receiving biological response modifiers: overview of nursing care. Onc Nurs Forum 1987; 14(6Suppl):32-37.

Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A, Jurecka-Lubieniecka B, Hass Lazar K, Turksa M, Zajusz A. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging, 2003; 30(8)1077-1086.

Jarząb B, Handkiewicz-Junak D, Włoch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocrine-Related Cancer 2005; 12:773-803.

Jassak PF. Future trends in biotherapy. Onc Nurs Forum 1987; 14(6Suppl):38-40.

Jentzen W, Freudenberg L, Bockisch A. Quantitative imaging of 124I with PET/ CT in pretherapy lesion dosimetry Effects impairing image quantification and their corrections. Q J Nucl Med Mol Imaging 2011; 55:21-43.

Jentzen W, Freudenberg L, Eising EG, Sonnenschein W., Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2008; 49:1017-1023.

Jentzen W, Weise R, Kupferschläger J, Freudenberg L, Brandau W, Bares R, Burchert W, Bockisch A. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D Modes for PET(/CT) systems. Eur J Nucl Med Molec Imag 2008; 35:611-623.

Kirkwood, JM & Ernstoff, MS. The role of interferon in the biotherapy of solid tumors. Onc Nurs Forum 1988; 15(6Suppl):3-6.

Kutz A, Grolimund E, Christ-Crain M, Thomann R, Falconnier C, Hoess C, Henzen C, Zimmerli W, Mueller B, Schuetz P. Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients. BMC Anesthesiology 2014; 14:102.

Laforgia N, Schettini F, De Matta D, Martinelli D, Ladisa G, Favia V. Lymphatic malformation in newborns as the first sign of diffuse lymphangiomatosis: successful treatment with sirolimus. Neonatology 2016; 109:52–55.

Lassmann M, Hänscheid H, Gassen D, Biko J, Meineke V, Reiners C, Scherthan H. In-vivog-H2AX and 53BP1 DNA repair focus formation in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2010; 51:1318–1325.

Lin L-F, Cheng C-Y, Hou C-H, Ku C-H, Tseng N-C, Shen DHY. Experience of low-dose aminophylline use to relieve minor adverse effects of dipyridamole in patients undergoing stress myocardial perfusion imaging. J Nucl Cardiol 2014; 21:563–569.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 9 of 17

Lippi F, Cappezone M, Angelini F, Taddei D, Molinaro E, Piunchera A, Pacini F. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001; 144(1):5-11.

Loescher LJ. Genetics in cancer prevention, screening and counseling: part I, genetics in prevention and screening. Onc Nurs Forum 1995; 22(2 Suppl):10-15.

Loescher LJ. Genetics in cancer prevention, screening and counseling: part II, the nurse’s role in genetic counseling. Onc Nurs Forum 1995; 22(2 Suppl):16-19.

Lynch, MT. The nurse’s role in the biotherapy of cancer: clinical trials and informed consent. Onc Nurs Forum 1988; 15(6Suppl):23-27.

Luster M. Present status of the use of recombinant human TSH in thyroid cancer management. Acta Oncologica 2006; 45:1018-1030.

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, Tennvall J., Bombardieri E. European Association of Nuclear Medicine Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med 2008; 10:1941-1959.

Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: A 130-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison with recombinant thyrotropin administration. Thyroid 2005; 15:1147-1155.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy, FM. Clinical value of 18-fluorine fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med 2010; 37(3):484-493.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy, FM. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010; 20:527-533.

Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer 2004; 12:49-64.

Luster M, Handkiewicz-Junak D, Grossi A, Zacharin M, Taïeb D, Cruz O, Hitzel A, Vallejo Casas JA, Mäder U, Dottorini ME for the Pediatric rhTSH Investigators Group. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study [brief report]. J Clin Endocrinol Metab, 2009; 94(10):3948-3953.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 10 of 17

McCabe, MS. Reimbursement of biotherapy: present status, future directions - perspectives of the hospital-based oncology nurse. Semin Onc Nurs 1992; 8(4 Suppl1):3-7.

McCaffrey D. Cancer nurse stress: a paradigm with relevance to investigational biotherapy. The Biotherapy of Cancer V, Oncology Nursing Press, 1992, pp.22-27.

Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, Moneti G, Cagnoli L. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney International 2004;65:1381-1385.

Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME. Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Molec Genet Metab, 2002; 77:91-98.

Mitsuyasu RT. The role of alpha interferon in the biotherapy of hematologic malignancies and AIDS-related Kaposi’s sarcoma. Onc Nurs Forum 1988; 15(6Suppl):7-12.

Mitsuyasu RT & Miles SA. Biotherapy with interferon in AIDS-related Kaposi’s sarcoma. Onc Nurs Forum 1987; 14(6Suppl):27-31.

Mitsuyasu RT. The enhanced potential use of recombinant alpha interferon in the treatment of AIDS-Related Kaposi’s sarcoma. Onc Nurs Forum 1989; 16(6Suppl):5-7.

Mrozek-Orlowski M, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Onc Nurs Forum 1999; 26(4):753-762.

Musholt TJ, Clerici T, Dralle H, Frilling A, Goretzki PE, Hermann MM, Kussmann J, Lorenz K, Nies C, Schabram J, Schabram P, Scheuba C, Simon D, Steinmuller T, Trupka AW, Wahl RA, Zielke A, Bockisch A, Karges W, Luster M, Schmid KW. German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg 2011; 396:639-649.

Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriques ALD, Eng CM, Tanaka H, Desnick RJ. Fabry disease: detection of undiagnosed patients undergoing chronic hemodialysis and identification of a “renal variant” phenotype. Kidney Intl 2003; 64(3):801-807.

Niederau C, Häussinger D. Gaucher’s disease: a review for the internist and hepatologist. Hepato-Gastroenterology 2000; 47:984-997.

Niederau C, vom Dahl S, Häussinger D. First long-term results of imiglucerase therapy of type 1 Gaucher disease. Euro J Medical Res 1998; 3:25-30.

Pacini F, Lippi F. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement. J Endocrinol Investigation 1999; 22(11 Suppl):25-29.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 11 of 17

Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 2005; 153:651-659.

Parkinson DR. The role of interleukin-2 in the biotherapy of cancer. Onc Nurs Forum 1989,16(6Suppl):16-20.

Pastores GM, Einhorn TA. Skeletal complications of Gaucher disease: pathophysiology, evaluation and treatment. Seminars in Hematology 1995; 32(3 Suppl 1):20-27.

Pazdur R, Jackson D, Shepherd B, Saddler D, Font L, McCardell M., Myers P, Schmidt S. Onc Nurs Forum 1991;18(1Suppl):11-17.

Perez EA, Hilllman, DW, Mailliard JA , Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR Randomized Phase II study of two irinotecan (cpt-11) schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004; 22:2849-2855.

Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Investigation 1999; 22(11 Suppl):30-34.

Petrich T, Korkmaz Z, Krull D, Frömke C, Meyer GJ, Knapp WH. In vitro experimental 211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seenin vivo against gemtuzumab ozogamicin. Eur J Nucl Med Mol Imaging 2010; 37:851-861.

Petrich T, Quintanilla-Martinez, Korkmaz Z, Samson E, Helmeke HJ, Meyer GJ, Knapp WH, Potter E. Effective cancer therapy with the alpha-particle emitter [211 At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin Canc Res 2006; 12:1342-1348.

Pfestroff A, Luster M, Jilg CA, Olbert PJ, Ohlmann CH, Lassmann M, Maecke HR, Ezzedin S, Bodei L on behalf of the Radionuclide Therapy Committee of the European Association of Nuclear Medicine. Current status and future perspectives of PSMA-targeted therapy in Europe:opportunity knocks. Eur J Nucl Med Molec Imaging 2015; 42:1971–1975.

Piciu D, Piciu A, Irimie A. 19-year-old female presenting differentiated thyroid carcinoma and primary amenorrhea due to Mayer-Rokitansky-Kuster-Hauser syndrome: a case report. J Med Case Reports 2012; 6:377.

Piciu A, Piciu D, Marlowe RJ, Irimie A. Highly-sensitive C-reactive protein, a biomarker of cardiovascular disease risk, in radically-treated differentiated thyroid carcinoma patients after repeated thyroid hormone withholding. Exper Clin Endocrinol Diab 2013; 121:102–108.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 12 of 17

Pitoia F, Marlowe RJ, Abelleira E, Faure EN, Bueno F, Schwarzstein D, Lutfi RJ, Niepomniszcze H. Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer. J Thyroid Res 2012.

Piper BF, Rieger PT, Brophy L, Haeuber D, Hood LE, Lyver A, Sharp E. Recent advances in the management of biotherapy-related side effects: fatigue. Onc Nurs Forum 1989; 6(6Suppl):27-34.

Rademakers RR. Radiologic evaluation of Gaucher bone disease. Seminars in Hematology 1995; 32(3 Suppl 1):14-19.

Rieger PT. Emerging strategies in the management of cancer. Onc Nurs Forum 1997; 24(4):712-718.

Rieger PT, Rumsey K. Responding to the educational needs of patients receiving biotherapy. the Biotherapy of Cancer V, Oncology Nursing Press, 1992; pp. 10-15.

Reiners C, Biko J, Haenscheid H, Hebestreit H, Kirinjuk S, Baranowski B, Marlowe RJ, Demidchik E, Drozd V, Demidchik Y. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very-high-risk radiation-induced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2013; 98:3039-3048.

Reiners C, Dietlein M, Luster M. Radioiodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab 2008; 22:989-1007.

Reiners C, Luster M, Lassmann M. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131. J Endocrinol Investigation 1999; 22(11 Suppl):17-24.

Risberg B. Adhesions: preventive strategies. Eur J Surgery 1997; 163 (Suppl 577):32-39.

Rivera E, Valero V, Francis D, Asnis AG, Schaaf LJ, Duncan B, Hortobagyi GN. Pilot study evaluating the pharmacokinetics, pharmacodynamics and safety of the combination of exemestane and tamoxifen. Clin Canc Res, 2004; 10:1943-1948.

Robinson KD, Posner JD. Patterns of self-care needs and interventions related to biologic response modifier therapy: fatigue as a model. Semin Onc Nurs 1992; 8(4 Suppl1): 17-22.

Roth MS, Foon KA. Biotherapy with interferon in hematologic malignancies. Onc Nurs Forum 1987; 14(6Suppl):16-22.

Samnick S, Romeike BF, Lehmann T, Israel I, Rübe C, Mautes A, Reiners C, Kirsch C-M. Efficacy of systemic radionuclide therapy with p-131I-iodo-l-phenylalanine combinedwith external beam photon irradiation in treating malignant gliomas. J Nucl Med 2009; 50:2025–

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 13 of 17

2032.

Sänger P, Schierz J-H, Marlowe RJ, Freesmeyer M. Detectability of Hypervascularity in Early Dynamic PET Depends on Tracer Kinetics: 18F-FDG Versus 68Ga-DOTATOC in Hepatic NET Metastasis. Liver International 2013; 34:161.

Schierz J-H, Opfermann T, Steenbeck J, Lopatta E, Settmacher U, Stallmach A, Marlowe RJ, Freesmeyer M. Early dynamic 18F-fluorodeoxyglucose positron emission tomography to detect hyperperfusion in hepatocellular carcinoma liver lesions. J Nucl Med 2012; 54:848-854.

Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Investigation 1999; 22(11 Suppl):3-7.

Schlumberger M, Berg G, Cohen C, et al. Follow-up of low risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 150:105-112.

Schlumberger MJ, Incerti C, Pacini F, Reiners C. The role of recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131. J Endocrinol Investigation 1999; 22(11 Suppl):35-41.Schlumberger M, Pacini F, Wiersinga WF, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004; 151:539-548.Schuetz P. Antibiotics for non-pneumonic respiratory-tract infections [Comment] Lancet Infect Dis 2013; 13:98-99.

Schuetz P, Braun N, Germann S, Baumgartner A, Muller B. Incorporation of nutritional factors and insulin resistance into insulin sliding scales in the non-critical care inpatient setting: a “before after” study. J Diabetes Metab 2014; 2: 325. doi:10.4172/2155-6156.1000325

Schuetz P, Friedli N, Grolimund E, Kutz A, Haubitz S, Christ-Crain M, Thomann R, Zimmerli W, Hoess C, Henzen C, Mueller B for the ProHOSP Study Group. Effect of hyperglycaemia on inflammatory and stress response and clinical outcomes of pneumonia inpatients in the non-critical care setting: Results from an observational cohort study. Diabetologica 2014; 275-284.

Schuetz P, Kutz A, Grolimund E, Haubitz S, Demann D, Vögeli A, Christ-Crain M, Thomann R,

Falconnier C, Hoess C, Henzen C, Marlowe RJ, Zimmerli W, Mueller B for the ProHOSP Study Group. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: Results from the randomized ProHOSP trial. Intl J Cardiol 2014; 175: 464-472.

Schuetz P, Litke A, Mueller B. Blood biomarkers for personalized treatment and management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013; 26:159-167.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 14 of 17

Schuetz P, Marlowe RJ, Mueller B. Proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clin Chem Lab Med 2014; 53: 521–539.

Schuetz P, Maurer P, Punjabi V, Desai A, Amin D, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Critical Care 2013, 17:R115.

Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit Car 2013; 19:453-460.

Siegenthaler J, Walti C, Urwyler SA, Schuetz P, Christ-Crain M. Copeptin concentrations during psychological stress: the PsyCo study. Eur J Endocrinol 2014; 171:737-742.

Stecker FF, Schierz J-H; Opfermann T, Driesch D, Hofmann GO, Winkens T, Freesmeyer M. Early dynamic 18F-FDG PET/CT to diagnose chronic osteomyelitis following lower extremity fractures. A pilot study. Nuklearmedizin 2013; 52.

Stolz D, Kostikas K, Blasi F, Boersma W, Milenkovic B, Lacoma A, Louis R, Aerts JG, Welte T, Torres A, Rohde GG, Boeck L, Rakic J, Scherr A, Hertel S, Giersdorf S, Tamm M. Adrenomedullin refines mortality prediction by the BODE index in COPD - The "BODE-A" index. Eur Respir J 2014; 43:397-408.

Strauman, JJ. The nurse’s role in the biotherapy of cancer: nursing research of side effects. Onc Nurs Forum 1988; 15(6Suppl):35-40.

Swan DK, Ford B. Chemoprevention of cancer: review of the literature. Onc Nurs Forum 1997; 24(4):719-727.

Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, Görges R. Health-related quality of life, depression and anxiety in thyroid cancer patients. Quality of Life Research 2006;15:695-703.

Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schöpper N, Bockisch A, Senf W, Görges R. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment [clinical study]. Eur J Endocrinol 2005; 153:755-763.

Terebelo HR. Alpha interferon: perspectives in the biotherapy of chronic myelogenous leukemia. Onc Nurs Forum 1991; 18(1Suppl):5-9.

Timper K, Fenske W, Kühn F, Frech N, Arici B, Rutishauser J, Kopp P, Allolio B, Stettler C, Müller B, Katan M, Christ-Crain M. Diagnostic accuracy of copeptin in the differential

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 15 of 17

diagnosis of the polyuria-polydipsia syndrome: a prospective multicenter study J Clin Endocrinol Metab 2015; 100: 2268–2274.

Tsevat JG, Lacasse CL. Understanding the special needs of patients receiving biotherapy: a conceptual model. The Biotherapy of Cancer V, Oncology Nursing Press, 1992, pp.5-9.

Vadhan-Raj S. Clinical applications of colony-stimulating factors. Onc Nurs Forum 1989; 16(6Suppl):21-26.

Vallejo Casas JA, Mena Bares LM, Gálvez MA, Marlowe RJ, Latre Romero JM , Martínez-Paredes M. Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of TSH stimulation methods. Nucl Med Commun 2011; 32:840-846.

Vallejo Casas JA, Mena Bares LM, Gálvez Moreno MA, Moreno Ortega, E, Marlowe RJ, Maza Muret FR, Albalá González MD, Thyroid remnant ablation success and disease outcome in Stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal. Quart J Nucl Med 2016; 60:163–171.

Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreißl MC, Reiners C, Luster M. Dosimetry-guided high-activity I-131 therapy in patients with advanced differentiated thyroidcarcinoma: initial experience. Eur J Nucl Med Molec Imag 2010; 37:896-903.

Verburg FA, Kirchgässner C, Hebestreit H, Steigerwald U, Lentjes EGWM, Ergezinger K, Grelle I, Reiners C, Luster M. Reference ranges for analytes of thyroid function in children. Hormone and Metab Res 2011; 43:422-426.

Verburg FA, Mäder U, Luster M, Reiners C. Primary tumor diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin Endocrinol, 2009; 71:291-297.

Verburg FA, Stokkel MPM, Düren C, Verkooijen RBT, Mäder U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M. No survival difference after successful I-131 ablation between initial low-risk and high-risk differentiated thyroid cancer patients. Eur J Nucl Med Molec Imag, 2010; 37:276-283. Viele CS. Chronic myelogenous leukemia and acute promyelocytic leukemia: new bone marrow transplantation options. Onc Nurs Forum 1996; 23(3):488-492.

Wadler S, Lyver A, Wiernik PH. Clinical toxicities of the combination of 5-fluorouracil and recombinant interferon alfa-2a: an unusual toxicity profile. Onc Nurs Forum 1989; 16(6Suppl): 12-15.

Walti C, Siegenthaler J, Christ-Crain M. Copeptin levels are independent of ingested nutrient

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 16 of 17

type after standardised meal administration – the CoMEAL study. Biomarkers 2014; 19: 557-562.

Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, Barth TF, Henne-Bruns D, Blagieva R, Böhm BO, Reske SN, Luster M. C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res. 2010;42(3):209-14.

Wheeler VS. Gene therapy: current strategies and future applications. Onc Nurs Forum 1995; 22(2 Suppl):20-27.

White CL. Symptom assessment and management of outpatients receiving biotherapy: the application of a symptom report form. Semin Onc Nurs 1992, 8(4 Suppl1):23-28.

Winkens T, Nietzsche S, Gottschaldt M, Freesmeyer M. Nonspecific iodine accumulation in surgical suture material mimicking follicular thyroid cancer bone metastasis in 131I scintigraphy. Clin Nucl Med 2014; 39:209–210.

Winningham ML. How exercise mitigates fatigue: implications for people receiving cancer therapy. The Biotherapy of Cancer V, Oncology Nursing Press, 1992, pp.16-21.

Winzeler B, Zweifel C, Nigro N, Arici B, Bally M, Schuetz P, Blum CA, Kelly C, Berkmann S, Huber A, Gentili F, Zadeh G, Landolt H, Mariani L, Muller B, Christ-Crain M. Postoperative copeptin concentration predicts diabetes insipidus after pituitary surgery. J Clin Endocrinol Metab 2015; 100: 2275-2282.

Wujcik D. Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia. Onc Nurs Forum 1996; 23(3):478-487.

Xistris, D. Reimbursement of biotherapy: Present status, future directions-perspectives of the office-based oncology nurse. Semin Onc Nurs 1992; 8(4 Suppl1):8-12.

Yasko, JM. Biological response modifier treatment reimbursement: present status and future strategies. Onc Nurs Forum 1988; 15(6Suppl):28-34.

Yasko, JM. A progress report on reimbursement of biotherapy: Prospects for the 1990s. Onc Nurs Forum 1989; 16(6Suppl):42-47.

Zagar I, Schwarzbartl-Pevec AA, Vidergar-Kralj B, Horvat R, Besic N. Recombinant human thyrotropin-aided radioiodine therapy in patients withmetastatic differentiated thyroid carcinoma J Thyroid Res 2012; 2012:670180.

Zaizov R, Frisch A, Cohen IJ. Lower-dose, high-frequency enzyme replacement therapy in children with type 1 Gaucher disease: experience at the Schneider Children’s Medical Center ofIsrael. Seminars in Hematology 1995; 32(3 Suppl 1):39–44.

Bibliography, Robert J. Marlowe/Spencer-Fontayne Corporation, 5 October 2016, Page 17 of 17

Zimmerli M, Tisljar K, Balestra G-M, Langewitz W, Marsch S, Hunziker S. Prevalence and risk factors for post-traumatic stress disorder in relatives of out-of-hospital cardiac arrest patients. Resuscitation 2014; 85:801–808.